Article in Circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Yogesh N V ReddyDepartment of Cardiovascular Medicine (Y.N.V.R., R.P.F., W.R.M., R.V., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0001-5322-0902
Robert P FrantzDepartment of Cardiovascular Medicine (Y.N.V.R., R.P.F., W.R.M., R.V., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0003-4128-3978
William R MirandaDepartment of Cardiovascular Medicine (Y.N.V.R., R.P.F., W.R.M., R.V., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0001-8864-8474
Aneesh K AsokanDivision of Endocrinology (A.K.A., K.S.N.), Mayo Clinic, Rochester, MN.ORCID 0009-0001-0147-4537
Revati VarmaDepartment of Cardiovascular Medicine (Y.N.V.R., R.P.F., W.R.M., R.V., B.A.B.), Mayo Clinic, Rochester, MN.
Franz RischardDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona, Tucson, AZ (F.R.).ORCID 0000-0002-6861-8304
Paul M HassounDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (P.M.H., S.C.M., M.M.).ORCID 0000-0003-0601-4975
Anna R HemnesDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN (A.R.H.).ORCID 0000-0002-2755-5845
Evelyn HornPerkin Heart Failure Center, Division of Cardiology, Weill Cornell Medicine, New York, NY (E.H.).ORCID 0000-0002-5751-9415
Jane A LeopoldDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.A.L.).ORCID 0000-0003-0598-8882
Erika B RosenzweigDepartment of Pediatrics and Medicine, Columbia University, New York, NY (E.B.R.).ORCID 0000-0003-4849-214X
Nicholas S HillDivision of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, MA (N.S.H.).ORCID 0000-0002-8242-8339
Serpil C ErzurumDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (P.M.H., S.C.M., M.M.).ORCID 0000-0001-5202-9065
Gerald J BeckDepartments of Quantitative Health Sciences (G.J.B., J.B.), Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-8876-5045
John BarnardDepartments of Quantitative Health Sciences (G.J.B., J.B.), Cleveland Clinic, Cleveland, OH.ORCID 0000-0003-2403-8268
Monica MukherjeeDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (P.M.H., S.C.M., M.M.).ORCID 0000-0001-6088-0773
W H Wilson TangCardiovascular Medicine (J.E.F., D.K., W.H.W.T.), Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-8335-735X
K Sreekumaran NairDivision of Endocrinology (A.K.A., K.S.N.), Mayo Clinic, Rochester, MN.
Barry A BorlaugDepartment of Cardiovascular Medicine (Y.N.V.R., R.P.F., W.R.M., R.V., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0001-9375-0596
Funding
Pulmonary Vascular Disease Phenomics Program (PVDOMICS) Data Coordinating CenterU01HL125177 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BECK, GERALD J, ERZURUM, SERPIL C. · 2014 to 2020
$20.0M
Pulmonary Hypertension in Left Heart DiseaseR01HL162828 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2023 to 2026
$3.1M
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4M
Mayo Clinic HeartShare Clinical CenterU01HL160226 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2021 to 2026
$1.8M
Intergrated Endothelial Phenotyping to Redefine Pulmonary HypertensionU01HL125215 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEOPOLD, JANE A, WAXMAN, AARON B · 2014 to 2018
$1.7M
PVDOMICS Defining the Future Fingerprints of Pulmonary Vascular DiseaseU01HL125218 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERMAN-ROSENZWEIG, ERIKA S., HORN, EVELYN · 2014 to 2018
$1.6M
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).U01HL125205 · NHLBI · MAYO CLINIC ROCHESTER · PI FRANTZ, ROBERT PAUL · 2014 to 2018
$1.5M
A molecular phenotype of combined pulmonary hypertensionU01HL125212 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEMNES, ANNA R, NEWMAN, JOHN HUGHES · 2014 to 2018
$1.5M
Phenomic and genomic study to subphenotype Hispanics with pulmonary hypertensionU01HL125208 · NHLBI · UNIVERSITY OF ARIZONA · PI GARCIA, JOE G. N., RISCHARD, FRANZ P · 2014 to 2018
$1.5M
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics ProgramU01HL125175 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M., MATHAI, STEPHEN C · 2015 to 2019
$1.1M
Peripheral Limitations in Pulmonary Hypertension and Effects of Muscle TrainingK23HL164901 · NHLBI · MAYO CLINIC ROCHESTER · PI Yogesh Nellore Vilambi Reddy · 2023 to 2026
backgroundWith pulmonary hypertension (PH), a pulmonary artery wedge pressure (PAWP)>15 mm Hg is used to diagnose left heart dysfunction, but some patients with adjudicated group 1 PH demonstrate PAWP>15 mm Hg. The primary objective of the study was to evaluate group 1 PH with high PAWP>15 mm Hg.
methodsPatients with adjudicated group 1 PH from PVDOMICS between 2016 and 2019 were separated into high PAWP(>15 mm Hg) or normal PAWP and compared with adjudicated combined pre- and postcapillary (Cpc) PH related to heart failure with preserved ejection fraction (HFpEF). Participants underwent dynamic right heart catheterization and metabolomics. Findings were validated in 3 independent cohorts with adjudicated group 1 PH (validation cohorts 1 and 2 with exercise right heart catheterization and validation cohort 3 with resting right heart catheterization).
resultsOf 325 patients with group 1 PH (73% women, mean age 53.0±14.3 years), 15% (n=48) had high PAWP. Group 1 PH+high PAWP demonstrated greater obesity, left ventricular hypertrophy (
conclusionsApproximately 1 in 5 adjudicated patients with group 1 PH has elevation in resting PAWP despite severe pulmonary vascular dysfunction and metabolomics consistent with traditionally defined group 1 PH. Despite resting PAWP elevation, these patients with group 1 PH were metabolomically and biologically distinct from Cpc PH HFpEF, with better left atrial function and diastolic reserve during exercise. These data emphasize the limitations of using resting PAWP alone to separate group 1 PH from HFpEF and call for development of more integrated clinical diagnostic criteria.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. · full record | OpenQuestion